Compounds > batyl alcohol
Page last updated: 2024-09-20

batyl alcohol

Description

batyl alcohol: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

batilol : An alkylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding octadecyl ether. It is used in cosmetics as a stabilising ingredient and skin-conditioning agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3681
CHEMBL ID1482516
CHEBI ID34117
SCHEMBL ID117051
MeSH IDM0103700

Synonyms (108)

Synonym
DIVK1C_001035
KBIO1_001035
NCI60_002329
SDCCGMLS-0066743.P001
SPECTRUM4_001778
SPECTRUM_001658
1-(octadecyloxy)-2,3-dihydroxypropane
nsc8716
glyceryl-1-octadecyl ether
stearyl monoglyceride
544-62-7
c18:0 glyceryl 1-ether
glycerol 1-octadecyl ether
nsc-8716
batilol
1, 3-(octadecyloxy)-
wln: q1yq1o18
batyl alcohol
glycerol monooctadecyl ether
1-o-octadecylglycerol
3-(octadecyloxy)-1,2-propanediol
.alpha.-octadecylether of glycerol
01503944_BATYL
3-octadecoxypropane-1,2-diol
NSC284200 ,
dl-batylalcohol
rac- 1-o-n-octadecyl glycerol
nsc-284200
IDI1_001035
BSPBIO_002296
ai3-18451
1,2-propanediol, 3-(octadecyloxy)-
nsc 284200
batilol [inn]
glycerine 1-monostearyl ether
einecs 208-874-7
monooctadecyl ether of glycerol
alpha-octadecylether of glycerol
brn 1725677
batilolum [inn-latin]
batyl alcohol, 99%
NCGC00095748-01
glycerol octadecyl ether
KBIO3_001516
KBIO2_002138
KBIOSS_002138
KBIO2_004706
KBIOGR_002296
KBIO2_007274
SPBIO_001617
SPECTRUM2_001609
NINDS_001035
SPECTRUM3_000738
SPECTRUM1503983
SPECTRUM5_000395
68990-53-4
NCGC00095748-02
b1202 ,
glycerol alpha-monostearyl ether
3-octadecyloxy-1,2-propanediol
ogbumnbnewymnj-uhfffaoysa-
inchi=1/c21h44o3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24-20-21(23)19-22/h21-23h,2-20h2,1h3
3-(octadecyloxy)propane-1,2-diol
CHEBI:34117 ,
batilolum
c18:0 glyceryl 1-ethe
HMS503O11
dtxcid508956
tox21_111515
dtxsid0047799 ,
cas-544-62-7
A830196
CHEMBL1482516
batylol
CCG-38893
4-01-00-02758 (beilstein handbook reference)
39yr661c4u ,
unii-39yr661c4u
FT-0632359
AKOS015901733
batyl alcohol [mi]
(+/-)-3-(octadecyloxy)-1,2-propanediol
batilol [who-dd]
batyl alcohol [inci]
SCHEMBL117051
tox21_111515_1
NCGC00095748-04
batylalcohol
W-105620
bathyl alcohol
dl-batyl alcohol
batil alcohol
3-octadecyloxypropane-1,2-diol
mfcd00004720
SR-05000002606-1
sr-05000002606
batyl alcohol;batilol
1-o-octadecyl-rac-glycerol
4-oxadocosane-1,2-diol
HY-W011175
Q27115823
AS-13696
CS-W011891
D81795
S3982
bdbm50535055
rac-glycerol 1-octadecyl ether
monoglycerides (125 mg)h1d2320.963mg/mg(ai)

Drug Classes (1)

ClassDescription
alkylglycerolA glycerol ether having at least one alkyl substituent on oxygen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency100.00000.141337.9142100.0000AID1490
AR proteinHomo sapiens (human)Potency5.80970.000221.22318,912.5098AID1259243; AID1259247; AID743040; AID743042; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.39730.000214.376460.0339AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.82100.000229.305416,493.5996AID743069; AID743075; AID743080; AID743091
67.9K proteinVaccinia virusPotency3.20270.00018.4406100.0000AID720579; AID720580
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.74980.001723.839378.1014AID743083
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency25.11890.65619.452025.1189AID927
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency25.11891.584913.004325.1189AID927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein foldingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
glycoprotein catabolic processPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein deglycosylationPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activityPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
metal ion bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
nucleusPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1632765Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1632764Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (31.37)18.7374
1990's9 (17.65)18.2507
2000's5 (9.80)29.6817
2010's14 (27.45)24.3611
2020's7 (13.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.88%)6.00%
Case Studies1 (1.96%)4.05%
Observational0 (0.00%)0.25%
Other47 (92.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
2-(3-pyridine)acetic acid[no description available]medium10monocarboxylic acid;
pyridines		human xenobiotic metabolite
ureidosuccinic acid[no description available]medium10aspartic acid derivative;
C4-dicarboxylic acid;
N-carbamoyl-amino acid		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite
arabinofuranosylcytosine triphosphate[no description available]medium10pyrimidine ribonucleoside monophosphate
aminoethylphosphonic acid[no description available]medium10phosphonic acids;
primary amino compound;
zwitterion		human metabolite;
metabolite;
mouse metabolite
gamma-guanidinobutyric acid[no description available]medium10guanidines;
monocarboxylic acid;
zwitterion		fungal metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
inositol[no description available]medium10cyclitol;
hexol
pentachlorophenol[no description available]medium10aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes		human xenobiotic metabolite
phenylalanine[no description available]medium10alpha-amino acid;
aromatic amino acid		Daphnia magna metabolite
nsc-267703[no description available]medium10anthracycline
n-acetyltryptophan[no description available]medium10N-acetyl-amino acid;
tryptophan derivative		metabolite
tyrphostin ag957[no description available]medium10aromatic amine
2-amino-4-phosphonobutyric acid[no description available]medium10
aristolochic acid i[no description available]medium10aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound		carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin
benzbromarone[no description available]medium101-benzofurans;
aromatic ketone		uricosuric drug
benzylhydrochlorothiazide[no description available]medium10benzenes;
benzothiadiazine;
organochlorine compound;
secondary amino compound;
sulfonamide
eucalyptol[no description available]medium10
amberlite cg 400[no description available]medium10methyl ester;
organic heteropentacyclic compound;
yohimban alkaloid
stallimycin[no description available]medium10
domperidone[no description available]medium10benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
ellipticine[no description available]medium10indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
glyphosate[no description available]medium10glycine derivative;
phosphonic acid		agrochemical;
EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor;
herbicide
haloperidol[no description available]medium10aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
miltefosine[no description available]medium10phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hypericin[no description available]medium10
imipramine[no description available]medium10dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
nsc 664704[no description available]medium10indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
ketoconazole[no description available]medium10dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
2-amino-3-phosphonopropionic acid[no description available]medium10alanine derivative;
non-proteinogenic alpha-amino acid;
phosphonic acids		human metabolite;
metabotropic glutamate receptor antagonist
benzylsuccinic acid[no description available]medium10dicarboxylic acidbacterial xenobiotic metabolite
beta-lapachone[no description available]medium10benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
mesoridazine[no description available]medium10phenothiazines;
sulfoxide;
tertiary amino compound		dopaminergic antagonist;
first generation antipsychotic
methoxsalen[no description available]medium10aromatic ether;
psoralens		antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
oxaprozin[no description available]medium101,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
penicillamine[no description available]medium10non-proteinogenic alpha-amino acid;
thiol
pentoxifylline[no description available]medium10oxopurine
phenolsulfonphthalein[no description available]medium102,1-benzoxathiole;
arenesulfonate ester;
phenols;
sultone		acid-base indicator;
diagnostic agent;
two-colour indicator
Picrotin, analytical standard[no description available]medium10furopyran
pomiferin[no description available]medium10isoflavanones
pridinol[no description available]medium10piperidines;
tertiary alcohol		antiparkinson drug;
muscle relaxant
sulfaquinoxaline[no description available]medium10benzenes;
sulfonamide
suramin[no description available]medium10naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
4-methylglutamic acid[no description available]medium10amino dicarboxylic acid;
glutamic acid derivative
pilocarpine hydrochloride[no description available]medium10hydrochloride
veratramine[no description available]medium10piperidine alkaloid
gibberellic acid[no description available]medium10C19-gibberellin;
gibberellin monocarboxylic acid;
lactone;
organic heteropentacyclic compound		mouse metabolite;
plant metabolite
santowhite powder[no description available]medium10
fentichlor[no description available]medium10aryl sulfide;
bridged diphenyl antifungal drug;
monochlorobenzenes;
polyphenol		antiinfective agent;
drug allergen
pyrrolidonecarboxylic acid[no description available]medium105-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
hexadecanolide[no description available]medium10macrolide
pamoic acid[no description available]medium10dicarboxylic acid
carzenide[no description available]medium10sulfonamide
estradiol 17 beta-cypionate[no description available]medium10steroid ester
lithocholic acid[no description available]medium10bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
jervine[no description available]medium10piperidines
bicuculline[no description available]medium10benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
salicylurate[no description available]medium10N-acylglycine;
secondary carboxamide		human xenobiotic metabolite;
uremic toxin
3,5-pyridinedicarboxylic acid[no description available]medium10pyridinedicarboxylic acid
ricinine[no description available]medium10nitrile;
pyridine alkaloid;
pyridone
carinamide[no description available]medium10
3,5-dibromotyrosine[no description available]medium10monocarboxylic acid
hematoporphyrin[no description available]medium10
1H-indazol-3-amine[no description available]medium10indazoles
1,1'-methylenedi-2-naphthol[no description available]medium10
tricarballylic acid[no description available]medium10tricarboxylic acid
popop[no description available]medium101,3-oxazolesfluorochrome
2-tert-butylhydroquinone[no description available]medium10hydroquinonesfood antioxidant
7-hydroxychlorpromazine[no description available]medium10phenothiazines
cme-carbodiimide[no description available]medium10
cyclacillin[no description available]medium10penicillinantibacterial drug
strombine[no description available]medium10
thymolphthalein[no description available]medium10terpene lactone
1,4,5,8-naphthalenetetracarboxylic acid[no description available]medium10
(7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione[no description available]medium10anthracycline
hydroxyphenylazouracil[no description available]medium10
canadine[no description available]medium10aromatic ether;
berberine alkaloid;
organic heteropentacyclic compound;
oxacycle
pimonidazole[no description available]medium10
flavone acetic acid[no description available]medium10
trichlorophene[no description available]medium10
verapamil hydrochloride[no description available]medium10
4-aminomethylbenzoic acid[no description available]medium10benzoic acids
cedrol[no description available]medium10cedrane sesquiterpenoid;
tertiary alcohol
propazole[no description available]medium10benzimidazoles
reserpic acid[no description available]medium10yohimban alkaloid
pifexole[no description available]medium10
Diphenolic acid[no description available]medium10bisphenol
Melicopidine[no description available]medium10acridines
resorufin[no description available]medium10phenoxazine
vinburnine[no description available]medium10alkaloid
pacein[no description available]medium10
alantolactone[no description available]medium10naphthofuran;
olefinic compound;
sesquiterpene lactone		antineoplastic agent;
apoptosis inducer;
plant metabolite
2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide[no description available]medium10
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
stictic acid[no description available]medium10aromatic ether
gallocyanine[no description available]medium10
propylsulfonic acid[no description available]medium10
1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide[no description available]medium10carbodiimide;
morpholines		cross-linking reagent
6,6'-dithiodinicotinic acid[no description available]medium10
va 061[no description available]medium10
n-acetyltyrosine, (dl)-isomer[no description available]medium10N-acetyl-amino acid;
phenols;
tyrosine derivative		human urinary metabolite
cinchonine[no description available]medium10(8xi)-cinchonan-9-ol;
cinchona alkaloid		metabolite
n(6)-(delta(2)-isopentenyl)adenine[no description available]medium106-isopentenylaminopurinecytokinin
2-Phthalimidoglutaricacid[no description available]medium10glutamic acid derivative
nsc-87877[no description available]medium10
methyl lithocholate[no description available]medium10
nipecotic acid amide[no description available]medium10piperidinecarboxamide
dimethacrine[no description available]medium10acridines
dehydroabietic acid[no description available]medium10abietane diterpenoid;
carbotricyclic compound;
monocarboxylic acid		allergen;
metabolite
4-deoxypyridoxine 5'-phosphate[no description available]medium10
4-(phenylthio)butanoic acid[no description available]medium10
bis-a-tda[no description available]medium10
1-amino-2-phenylethylphosphonic acid[no description available]medium10
4-fluoro-alpha-hydroxybenzeneacetic acid[no description available]medium10
Isopteropodin[no description available]medium10indolizines
benzpiperylone[no description available]medium10pyrazoles;
ring assembly
carboxyamido-triazole[no description available]medium10
nsc 607097[no description available]medium10
pacifenol[no description available]medium10
n-phenyliminodiacetic acid[no description available]medium10
cyc 202[no description available]medium102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cystamine hydrochloride[no description available]medium10
dipiperidinoethane-di-n-oxide[no description available]medium10
benzyl-beta-d-xyloside[no description available]medium10
2,2'-(3-methylcyclohexane-1,1-diyl)diacetic acid[no description available]medium10dicarboxylic acid
2,4-dinitrophenylacetic acid[no description available]medium10
sitosterol, (3beta)-isomer[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol		anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor
(5-Phenyl-1,2,4-triazol-3-yl)urea[no description available]medium10benzenes
fumagillol[no description available]medium10secondary alcohol;
sesquiterpenoid;
spiro-epoxide		antimicrobial agent
vacquinol-1[no description available]medium10
aspidospermine[no description available]medium10indole alkaloid
guaiol[no description available]medium10guaiane sesquiterpenoid
benzatropine methanesulfonate[no description available]medium10
pseudoyohimbine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylate
gant58[no description available]medium10pyridines
nsc 88915[no description available]medium10
o-acetylsolasodine[no description available]medium10
viroallosecurinine[no description available]medium10indolizines
4-methyl-2-quinazolinamine[no description available]medium10
1-amino-9,10-dioxo-4-(3-sulfamoylanilino)anthracene-2-sulfonic acid[no description available]medium10
adamantoylcytarabine[no description available]medium10
6,11-dioxo-12-naphtho[2,3-b]indolizinecarboxylic acid ethyl ester[no description available]medium10naphthalenes
noscapine[no description available]medium10aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
LSM-1290[no description available]medium10benzazepine alkaloid;
cyclic acetal
2-glycineamide-5-chlorophenyl-2-pyrryl ketone[no description available]medium10
nsc 154020[no description available]medium10N-glycosyl compound
4-[(1-naphthalenylamino)-oxomethyl]benzene-1,3-dicarboxylic acid[no description available]medium102-hydroxyisophthalic acid
2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one[no description available]medium10cyclic ketone;
quinuclidines
5-(1,3-benzodioxol-5-yl)-N-(2,4-dimethylphenyl)-1,3,4-oxadiazol-2-amine[no description available]medium10benzodioxoles
croton factor f1[no description available]medium10phorbol ester;
tertiary alpha-hydroxy ketone
medicarpin[no description available]medium10medicarpinplant metabolite
gitoxigenin[no description available]medium1014beta-hydroxy steroid;
16beta-hydroxy steroid;
3beta-hydroxy steroid
aromoline[no description available]medium10
nsc668394[no description available]medium10
gant 61[no description available]medium10aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
nortriptyline hydrochloride[no description available]medium10organic tricyclic compoundgeroprotector
nsc 45641[no description available]medium10
geraniol[no description available]medium103,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component
aconitic acid[no description available]medium10aconitic acidfundamental metabolite
amygdalin[no description available]medium10
alpha-phenylcinnamate[no description available]medium10
curcumin[no description available]medium10aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
ethyldimethylaminopropyl carbodiimide[no description available]medium10
tamoxifen citrate[no description available]medium10citrate saltangiogenesis inhibitor;
anticoronaviral agent
eskazine[no description available]medium10
nsc 336628[no description available]medium10
1,3-dimethyl-8-[2-(1-pyrrolidinyl)ethylthio]-6-sulfanylidene-7H-purin-2-one[no description available]medium10oxopurine
cambinol[no description available]medium10
nsc 117199[no description available]medium10
mangostin[no description available]medium10aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
coumestrol[no description available]medium10coumestans;
delta-lactone;
polyphenol		anti-inflammatory agent;
antioxidant;
plant metabolite
rottlerin[no description available]medium10aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
ellagic acid[no description available]medium10catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol		antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent
7,8-dimethylalloxazine[no description available]medium107,8-dimethylbenzo[g]pteridine-2,4-dioneplant metabolite
dihydrothobainone[no description available]medium10
piperic acid[no description available]medium10alpha,beta-unsaturated monocarboxylic acid;
benzodioxoles		plant metabolite
abscisic acid[no description available]medium10abscisic acids
radicinin[no description available]medium10aromatic ketone
5,6-dichloro-1H-imidazo[4,5-b]pyrazine-2-carboxylic acid[no description available]medium10imidazopyrazine
hispanolone[no description available]medium10
veratridine[no description available]medium10
zimelidine hydrochloride[no description available]medium10
chlortetracycline hydrochloride[no description available]medium10
viridicatumtoxin[no description available]medium10
dacarbazine[no description available]medium10dacarbazine
hematein[no description available]medium10
castanospermine[no description available]medium10indolizidine alkaloidanti-HIV-1 agent;
anti-inflammatory agent;
EC 3.2.1.* (glycosidase) inhibitor;
metabolite
dactinomycin[no description available]medium10actinomycinmutagen
3-nitrotyrosine[no description available]medium102-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid
tyrosine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
chimyl alcohol[no description available]medium40alkylglycerol
naproxen[no description available]medium10methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
piroxicam[no description available]medium10benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
glycyrrhizic acid[no description available]medium10enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
phytanic acid[no description available]medium10branched-chain saturated fatty acid;
long-chain fatty acid;
methyl-branched fatty acid
sesquiterpenes[no description available]medium10
gorgosterol[no description available]medium10steroid
cystamine[no description available]medium10organic disulfide;
primary amino compound		EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
selachyl alcohol[no description available]medium10alkylglycerol
pentoxyl[no description available]medium10pyrimidone
thiotepa[no description available]medium10aziridines
leukogen[no description available]medium20
thiazolidines[no description available]medium20thiazolidine
1-anilino-8-naphthalenesulfonate[no description available]medium20aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
didanosine[no description available]medium10purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
uracil[no description available]medium20pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
guanine[no description available]medium102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine[no description available]medium10pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
cetyl alcohol[no description available]medium20hexadecanol;
long-chain primary fatty alcohol		algal metabolite;
flavouring agent;
human metabolite;
plant metabolite
dihydroxyacetone[no description available]medium10ketotriose;
primary alpha-hydroxy ketone		antifungal agent;
Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
stearyl alcohol[no description available]medium10long-chain primary fatty alcohol;
octadecanol		algal metabolite;
human metabolite;
plant metabolite
glucosamine[no description available]medium20D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
6-methyltetrahydropterin[no description available]medium20pterins
1-hexadecyl-2-acetyl-glycero-3-phosphocholine[no description available]medium302-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
adenine[no description available]medium106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
azathioprine[no description available]medium10aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
allantoin[no description available]medium10imidazolidine-2,4-dione;
ureas		Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary
oleic acid[no description available]medium10octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
edelfosine[no description available]medium10glycerophosphocholine
n-formylmethionine leucyl-phenylalanine[no description available]medium10tripeptide
monolaurin[no description available]medium101-monoglyceride;
dodecanoate ester;
rac-1-monoacylglycerol
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Confusional Senile Dementia0low10
Adrenoleukodystrophy, Autosomal Neonatal Form0low10
Adrenoleukodystrophy, Autosomal, Neonatal Form0low10
Adrenoleukodystrophy, Neonatal0low10
Alzheimer Dementia0low10
Alzheimer Disease0low10
Alzheimer Disease, Early Onset0low10
Alzheimer Disease, Late Onset0low10
Alzheimer Sclerosis0low10
Alzheimer Syndrome0low10
Alzheimer Type Senile Dementia0low10
Alzheimer-Type Dementia (ATD)0low10
Alzheimer's Disease0low10
Alzheimer's Disease, Focal Onset0low10
Alzheimer's Diseases0low10
Anemia0low10
Anemia, Aplastic0low10
Anemia, Fanconi0low10
Anemia, Hypoplastic0low10
Aortic Diseases0low10
Aplastic Anaemia0low10
Aplastic Anemia0low10
Arrhythmia0low10
Arrhythmias, Cardiac0low10
Arrythmia0low10
Atherogenesis0low10
Atheroma0low10
Atheromatous Plaque0low10
Atheromatous Plaques0low10
Atherosclerosis0low10
Atherosclerotic Plaque0low10
Atherosclerotic Plaques0low10
Benign Neoplasms0low10
Cadaver0low10
Cancer0low10
Cardiac Arrhythmia0low10
Cardiac Arrhythmias0low10
Cardiac Dysrhythmia0low10
Cardiac Hypertrophy0low10
Cardiac Remodeling, Ventricular0low10
Cardiomegaly0low10
Chondrodysplasia Punctata, Rhizomelic0low20
Chondrodysplasia Punctata, Rhizomelic Form0low20
Complication, Postoperative0low10
Congenital Icthyosis Mental Retardation Spasticity Syndrome0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Corpse0low10
Dementia, Alzheimer Type0low10
Dementia, Presenile0low10
Dementia, Primary Senile Degenerative0low10
Dementia, Senile0low10
Disease Models, Animal0low40
Early Onset Alzheimer Disease0low10
Enlarged Heart0low10
FALDH Deficiency0low10
Familial Alzheimer Disease (FAD)0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Fatty Aldehyde Dehydrogenase Deficiency0low10
Fatty Aldehyde Dehydrogenase Deficiency Disease0low10
Fatty Streak, Arterial0low10
Fever, Zika0low10
Fibroatheroma0low10
Fibroatheromatous Plaques0low10
Focal Onset Alzheimer's Disease0low10
Heart Enlargement0low10
Heart Hypertrophy0low10
Hyperpipecolatemia0low10
Hyperpipecolic Acidemia0low10
Ichthyosis Oligophrenia Syndrome0low10
Ichthyosis, Spastic Neurologic Disorder, and Oligophrenia0low10
Injuries, Radiation0low20
Late Onset Alzheimer Disease0low10
Left Ventricle Remodeling0low10
Left Ventricular Remodeling0low10
Leukocyte Disorders0low10
Leukocytopenia0low20
Leukopenia0low20
Lipid Metabolism, Inborn Error0low10
Lipid Metabolism, Inborn Errors0low10
Malignancy0low10
Malignant Neoplasms0low10
Myocardial Remodeling, Ventricular0low10
Neonatal Adrenoleukodystrophy0low10
Neoplasia0low10
Neoplasm0low10
Neoplasms0low10
Neoplasms, Benign0low10
Peroxisomal Disorders0low10
Peroxisomal Dysfunction, General0low10
Peroxisomal Dysfunction, Multiple0low10
Peroxisomal Dysfunction, Single0low10
Plaque, Atherosclerotic0low10
Postoperative Complications0low10
Pregnancy0low20
Presenile Alzheimer Dementia0low10
Primary Senile Degenerative Dementia0low10
Radiation Injuries0low20
Radiation Sickness0low20
Radiation Syndrome0low20
Respiratory Tract Diseases0low10
Rhizomelic Chondrodysplasia Punctata0low20
Senile Dementia, Acute Confusional0low10
Senile Dementia, Alzheimer Type0low10
Sjogren-Larsson Syndrome0low10
Sju00F6gren-Larsson Syndrome0low10
Tumors0low10
Ventricle Remodeling0low10
Ventricular Remodeling0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]